DK1471902T3 - Sammensætninger til brug i fremgangsmåder til behandling af høretab - Google Patents

Sammensætninger til brug i fremgangsmåder til behandling af høretab

Info

Publication number
DK1471902T3
DK1471902T3 DK03701231.7T DK03701231T DK1471902T3 DK 1471902 T3 DK1471902 T3 DK 1471902T3 DK 03701231 T DK03701231 T DK 03701231T DK 1471902 T3 DK1471902 T3 DK 1471902T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
hearing loss
treating hearing
treating
Prior art date
Application number
DK03701231.7T
Other languages
English (en)
Inventor
Jonathan Kil
Eric D Lynch
Original Assignee
Sound Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sound Pharmaceuticals Inc filed Critical Sound Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1471902T3 publication Critical patent/DK1471902T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK03701231.7T 2002-01-04 2003-01-03 Sammensætninger til brug i fremgangsmåder til behandling af høretab DK1471902T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34581302P 2002-01-04 2002-01-04
PCT/US2003/000308 WO2003057207A1 (en) 2002-01-04 2003-01-03 Methods for treating hearing loss

Publications (1)

Publication Number Publication Date
DK1471902T3 true DK1471902T3 (da) 2014-09-08

Family

ID=23356596

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03701231.7T DK1471902T3 (da) 2002-01-04 2003-01-03 Sammensætninger til brug i fremgangsmåder til behandling af høretab

Country Status (12)

Country Link
US (2) US6815434B2 (da)
EP (1) EP1471902B1 (da)
JP (1) JP4414229B2 (da)
KR (1) KR20040078663A (da)
CN (1) CN1635882B (da)
AU (1) AU2003202219B2 (da)
CA (2) CA2825792C (da)
DK (1) DK1471902T3 (da)
ES (1) ES2497716T3 (da)
HK (1) HK1072360A1 (da)
PT (1) PT1471902E (da)
WO (1) WO2003057207A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1461033B1 (en) * 2001-11-29 2013-02-27 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DK1471902T3 (da) * 2002-01-04 2014-09-08 Sound Pharmaceuticals Inc Sammensætninger til brug i fremgangsmåder til behandling af høretab
EP1645276A1 (en) * 2004-10-08 2006-04-12 Wageningen Centre for Food Sciences Treatment of neurodegenerative disorders
CN1303898C (zh) * 2004-12-29 2007-03-14 李浙烽 复合预混料
JP2008533021A (ja) * 2005-03-08 2008-08-21 サウンド ファーマシューティカルズ インコーポレイテッド 癌を治療するための方法および組成物
US20070021352A1 (en) * 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
US20070123555A1 (en) * 2005-09-30 2007-05-31 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
WO2007044700A2 (en) * 2005-10-07 2007-04-19 Board Of Trustees Of Southern Illinois University Protectant combinations for reducing toxicities
US8338397B2 (en) * 2006-01-19 2012-12-25 The Regents Of The University Of Michigan Composition and method of treating side effects from antibiotic treatment
US7951845B2 (en) * 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
US8927528B2 (en) 2006-01-19 2015-01-06 The Regents Of The University Of Michigan Composition for treating hearing loss
US9919008B2 (en) 2006-01-19 2018-03-20 The Regents Of The University Of Michigan Method for treating age-related hearing loss (ARHL)
US20090155390A1 (en) * 2006-01-19 2009-06-18 Miller Josef M Composition and method of treating temporary and permanent hearing loss
USRE46372E1 (en) 2006-01-19 2017-04-25 The Regents Of The Univerity Of Michigan Method for treating hearing loss
US10238599B2 (en) 2006-01-19 2019-03-26 The Regents Of The University Of Michigan Composition and method for treating congenital cytomegalovirus induced hearing loss
US9889156B2 (en) 2006-01-19 2018-02-13 The Regents Of The University Of Michigan Method for treating noise-induced hearing loss (NIHL)
US9770433B2 (en) 2006-01-19 2017-09-26 The Regents Of The University Of Michigan Composition and method for treating tinnitus
HUE049307T2 (hu) 2006-01-27 2020-09-28 Univ California Bélben oldódó bevonattal ellátott ciszteamin-bitartrát és cisztamin
US20100129467A9 (en) * 2007-08-31 2010-05-27 Albritton Iv Ford D Nutritional supplement
AR069500A1 (es) 2007-11-30 2010-01-27 Univ California Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteamina
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
US20180161459A1 (en) * 2014-08-29 2018-06-14 Sound Pharmaceuticals Incorporated Methods of Screening for Drugs to Prevent Noise-Induced Hearing Loss
KR101893604B1 (ko) * 2015-08-27 2018-08-30 경희대학교 산학협력단 칸디다 유틸리스 추출물을 포함하는 난청의 예방 또는 치료용 조성물
WO2017087532A1 (en) 2015-11-16 2017-05-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
CN109475518A (zh) * 2016-05-18 2019-03-15 桑得医药品公司 梅尼埃病的治疗
CN114848836B (zh) * 2021-07-06 2023-09-15 中山大学孙逸仙纪念医院 一种偶联物及其在治疗内耳疾病上的应用
IT202200018339A1 (it) * 2022-09-08 2024-03-08 Univ Degli Studi Di Trento Composti del selenio e dello zolfo quali inibitori del riconoscimento degli RNA modificati da N6-metiladenosina da parte delle proteine YTHDF

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3027073C2 (de) * 1980-07-17 1985-03-07 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische Präparate, enthaltend 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
DE3670635D1 (de) * 1985-04-27 1990-05-31 Nattermann A & Cie Neue benzisoselenazolonyl-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DE3638124C2 (de) 1986-11-08 1996-09-05 Nattermann A & Cie Neue pharmazeutische Verwendung von Ebselen
US5385726A (en) * 1990-08-06 1995-01-31 Rhone-Poulenc Rorer Gmbh Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
DE4024885C2 (de) 1990-08-06 2002-07-18 Nattermann A & Cie Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
DE19856210A1 (de) * 1998-10-26 2000-04-27 Albert Lind Verwendung von Thiolverbindungen, Oxidoreduktasen und/oder Hydrolasen zur Behandlung des Tinnitus, insbesondere des chronischen Tinnitus
AU5391901A (en) 2000-04-26 2001-11-07 Univ Oregon Health Sciences Administration of a thiol-based chemoprotectant compound
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
EP1461033B1 (en) * 2001-11-29 2013-02-27 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DK1471902T3 (da) 2002-01-04 2014-09-08 Sound Pharmaceuticals Inc Sammensætninger til brug i fremgangsmåder til behandling af høretab
WO2004080486A1 (ja) 2003-03-13 2004-09-23 Mitsubishi Pharma Corporation 腫瘍形成抑制剤
US20050147978A1 (en) * 2003-12-30 2005-07-07 Jose Remacle Method for quantitative determination of multi-drug resistance in tumors

Also Published As

Publication number Publication date
US20030162747A1 (en) 2003-08-28
EP1471902B1 (en) 2014-07-02
AU2003202219B2 (en) 2008-10-23
CA2825792C (en) 2016-08-16
JP2005516028A (ja) 2005-06-02
CA2472678A1 (en) 2003-07-17
CA2472678C (en) 2013-12-03
US7820640B2 (en) 2010-10-26
KR20040078663A (ko) 2004-09-10
HK1072360A1 (en) 2005-08-26
PT1471902E (pt) 2014-09-09
ES2497716T3 (es) 2014-09-23
EP1471902A1 (en) 2004-11-03
US6815434B2 (en) 2004-11-09
EP1471902A4 (en) 2007-05-23
AU2003202219A1 (en) 2003-07-24
US20040220145A1 (en) 2004-11-04
CN1635882A (zh) 2005-07-06
CA2825792A1 (en) 2003-07-17
WO2003057207A1 (en) 2003-07-17
JP4414229B2 (ja) 2010-02-10
CN1635882B (zh) 2010-11-10

Similar Documents

Publication Publication Date Title
DK1471902T3 (da) Sammensætninger til brug i fremgangsmåder til behandling af høretab
DK1390014T3 (da) Sammensætning til anvendelse i en fremgangsmåde til behandling af hyperplasi
NO20044148L (no) Sammensetning og fremgangsmate for bronnrensing
DK1791791T3 (da) Fremgangsmåder og sammensætninger til behandling af vand
HK1100262A1 (en) Methods and compositions for the treatment and management of hemoglobinopathy and anemia
GB2421260B (en) Well treating compositions for slow release of treatment agents and methods of using the same
DK1485127T3 (da) Anvendelse af midler til behandling af inflammation
DK1505975T3 (da) Sammensætninger og fremgangsmåde til behandling af infektioner i kvæg og svin
DK1638999T3 (da) Sammensætninger og fremgangsmåder til øgning af knoglemineralisering
IS7717A (is) Pýrídasínónafleiður sem PDF4-hemlar
DK1499184T3 (da) Sammensætninger til behandling af ektoparasitangreb
DK1294644T3 (da) Vandbehandlingssammensætninger
IL166608A0 (en) Anti-microbial compositions and methods of using same
DK1667730T3 (da) Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom
AU2003271944A1 (en) Methods for making water treatment compositions and compositions thereof
DK1530466T3 (da) Anvendelse af nintedanib til behandling af lungefibrose
DK1478438T3 (da) Fremgangsmåder og sammensætninger til behandling af astma
DK1539200T3 (da) Fremgangsmåde til behandling af multipel sklerose
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
ATE399523T1 (de) Haarbehandlungszusammensetzung
DK1461047T3 (da) Sammensætninger og fremgangsmåde til behandling af dyr
DK1337228T3 (da) Sammensætninger til fjernelse af human cerumen
ATE395899T1 (de) Haarbehandlungszusammensetzungen
DE60305300D1 (de) Haarbehandlungszusammensetzungen
ITRI20030008A1 (it) Impianto dentale monofasico ad ubica struttura comprensiva di moncone totalmente o parzialmentee precostruito.